Fluoxetine addition to methadone in addicts: Pharmacokinetic aspects

Therapeutic Drug Monitoring

Volumn 18, Issue 5, 1996, Pages 570-572

  Bertschy, G ^a   Eap, C B ^a   Powell, K ^a   Baumann, P ^a  

^a DEPT UNIV DE PSYCHIATRIE ADULTE   (Switzerland)

Author keywords

Addiction; Depression; Fluoxetine; Methadone; Pharmacokinetic interaction

Indexed keywords

FLUOXETINE; FLUVOXAMINE; METHADONE;

ADULT; AFFECTIVE NEUROSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DEPENDENCE; FEMALE; HUMAN; MALE; METHADONE TREATMENT; PRIORITY JOURNAL;

ADULT; ANALGESICS, OPIOID; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DRUG INTERACTIONS; FEMALE; FLUOXETINE; FLUVOXAMINE; HUMANS; MALE; METHADONE; MOOD DISORDERS; SEROTONIN UPTAKE INHIBITORS; SUBSTANCE-RELATED DISORDERS;

EID: 0029738846     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199610000-00008     Document Type: Article

References (16)

1. Bertschy G, Baumann P, Eap CB, Baettig D. Probable metabolic interaction between methadone and fluvoxamine in addict patients. Ther Drug Monit 1994;16:42-5.
2. Bergstrom RF, Peyton AL, Lemberger L. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 1992;51:239-48.
3. Vandel S, Bertschy G, Bonin B, et al. Tricyclic antidepressant plasma levels after fluoxetine addition. Neuropsychobiology 1992;25:202-7.
4. Nilsson ML, Änggård E, Holmstrand J, Gunne LM. Pharmacokinetics of methadone during maintenance treatment: adaptive changes during the induction phase. Eur J Clin Pharmacol 1982;22:343-9.
5. Batki SL, Manfredi LB, Peyton J, Jones RT. Fluoxetine or cocaine dependence in methadone maintenance: quantitative plasma and urine cocaine/benzoylecogomine concentrations. J Clin Psychopharmacol 1993;13:243-50.
6. Lemberger L, Bergstrom RF, Wolen RL, Farid NA, Enas GG, Aronoff GR. Fluoxetine: clinical pharmacology and physiologic disposition. J Clin Psychiatry 1985;46:14-9.
7. Olsen GO, Wendel HA, Livermore JD, Leger RM, Lynn RK, Gerber N. Clinical effects and pharmacokinetics of racemic methadone and its optical isomers. Clin Pharmacol Ther 1977;21:147-57.
8. Kristensen K, Angelo HR. Stereospecific gas Chromatographic method for determination of methadone in serum. Chirality 1992;4:263-7.
9. Bertschy G, Vandel S, Vandel B, Allers G, Volmat R. Fluvoxamine-tricyclic antidepressant interaction: an accidental finding. Eur J Clin Pharmacol 1991;40:119-20.
10. Härtter S, Wetzel H, Hammes E, Hiemke CH. Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients. Psychopharmacology 1993; 110:302-8.
11. Crewe HK, Lennard MS, Tucher GT, Woods FR, Haddock RE. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992;34:262-5.
12. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993;45:1211-4.
13. Vandel S, Bertschy G, Baumann P, et al. Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. Pharmacol Res 1995;31:347-53.
14. Moffat AC, Jackson JV, Moss MS, Widdop B, Greenfield ES. Clarke's isolation and identification of drugs in pharmaceuticals, body fluid and post-mortem material. London: Pharmaceutical Press, 1986.
15. Maany I, Dhopesh V, Arndt IO, Burke W, Woody G, O'Brien CP. Increase in desipramine serum levels associated with methadone treatment. Am J Psychiatry 1989;146:1611-3.
16. Wu D, Otton SV, Sproule BA, et al. Inhibition of human cytochrome P4502D6 (CYP2D6) by methadone. Br J Clin Pharmacol 1993;35:30-4.